Active cancer as the main predictor of mortality for COVID-19 in oncology patients in a specialized center.

IF 2.3 4区 医学 Q3 ONCOLOGY
Pathology & Oncology Research Pub Date : 2023-09-07 eCollection Date: 2023-01-01 DOI:10.3389/pore.2023.1611236
Freddy Villanueva-Cotrina, Juan Velarde, Ricardo Rodriguez, Alejandra Bonilla, Marco Laura, Tania Saavedra, Diana Portillo-Alvarez, Yovel Bustamante, Cesar Fernandez, Marco Galvez-Nino
{"title":"Active cancer as the main predictor of mortality for COVID-19 in oncology patients in a specialized center.","authors":"Freddy Villanueva-Cotrina,&nbsp;Juan Velarde,&nbsp;Ricardo Rodriguez,&nbsp;Alejandra Bonilla,&nbsp;Marco Laura,&nbsp;Tania Saavedra,&nbsp;Diana Portillo-Alvarez,&nbsp;Yovel Bustamante,&nbsp;Cesar Fernandez,&nbsp;Marco Galvez-Nino","doi":"10.3389/pore.2023.1611236","DOIUrl":null,"url":null,"abstract":"<p><p><b>Introduction:</b> The role of the type, stage and status of cancer in the outcome of COVID-19 remains unclear. Moreover, the characteristic pathological changes of severe COVID-19 reveled by laboratory and radiological findings are similar to those due to the development of cancer itself and antineoplastic therapies. <b>Objective:</b> To identify potential predictors of mortality of COVID-19 in cancer patients. <b>Materials and methods:</b> A retrospective and cross-sectional study was carried out in patients with clinical suspicion of COVID-19 who were confirmed for COVID-19 diagnosis by RT-PCR testing at the National Institute of Neoplastic Diseases between April and December 2020. Demographic, clinical, laboratory and radiological data were analyzed. Statistical analyses included area under the curve and univariate and multivariate logistic regression analyses. <b>Results:</b> A total of 226 patients had clinical suspicion of COVID-19, the diagnosis was confirmed in 177 (78.3%), and 70/177 (39.5%) died. Age, active cancer, leukocyte count ≥12.8 × 109/L, urea ≥7.4 mmol/L, ferritin ≥1,640, lactate ≥2.0 mmol/L, and lung involvement ≥35% were found to be independent predictors of COVID-19 mortality. <b>Conclusion:</b> Active cancer represents the main prognosis factor of death, while the role of cancer stage and type is unclear. Chest CT is a useful tool in the prognosis of death from COVID-19 in cancer patients. It is a challenge to establish the prognostic utility of laboratory markers as their altered values it could have either oncological or pandemic origins.</p>","PeriodicalId":19981,"journal":{"name":"Pathology & Oncology Research","volume":null,"pages":null},"PeriodicalIF":2.3000,"publicationDate":"2023-09-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10511753/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pathology & Oncology Research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3389/pore.2023.1611236","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/1/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction: The role of the type, stage and status of cancer in the outcome of COVID-19 remains unclear. Moreover, the characteristic pathological changes of severe COVID-19 reveled by laboratory and radiological findings are similar to those due to the development of cancer itself and antineoplastic therapies. Objective: To identify potential predictors of mortality of COVID-19 in cancer patients. Materials and methods: A retrospective and cross-sectional study was carried out in patients with clinical suspicion of COVID-19 who were confirmed for COVID-19 diagnosis by RT-PCR testing at the National Institute of Neoplastic Diseases between April and December 2020. Demographic, clinical, laboratory and radiological data were analyzed. Statistical analyses included area under the curve and univariate and multivariate logistic regression analyses. Results: A total of 226 patients had clinical suspicion of COVID-19, the diagnosis was confirmed in 177 (78.3%), and 70/177 (39.5%) died. Age, active cancer, leukocyte count ≥12.8 × 109/L, urea ≥7.4 mmol/L, ferritin ≥1,640, lactate ≥2.0 mmol/L, and lung involvement ≥35% were found to be independent predictors of COVID-19 mortality. Conclusion: Active cancer represents the main prognosis factor of death, while the role of cancer stage and type is unclear. Chest CT is a useful tool in the prognosis of death from COVID-19 in cancer patients. It is a challenge to establish the prognostic utility of laboratory markers as their altered values it could have either oncological or pandemic origins.

活跃的癌症是专业中心肿瘤患者新冠肺炎死亡率的主要预测因素。
简介:癌症的类型、分期和状态在新冠肺炎结局中的作用尚不清楚。此外,实验室和放射学结果揭示的严重新冠肺炎的特征性病理变化与癌症本身和抗肿瘤疗法的发展相似。目的:确定癌症患者新冠肺炎死亡率的潜在预测因素。材料和方法:对2020年4月至12月间在美国国家整形病研究所通过RT-PCR检测确诊为新冠肺炎的临床怀疑新冠肺炎患者进行了回顾性和横断面研究。分析了人口统计学、临床、实验室和放射学数据。统计分析包括曲线下面积、单变量和多变量逻辑回归分析。结果:临床怀疑新冠肺炎患者226例,确诊177例(78.3%),死亡70/177例(39.5%)。年龄、活动性癌症、白细胞计数≥12.8×109/L、尿素≥7.4 mmol/L、铁蛋白≥1640、乳酸≥2.0 mmol/L和肺部受累≥35%被发现是新冠肺炎死亡率的独立预测因素。结论:活动性癌症是死亡的主要预后因素,但癌症分期和类型的作用尚不明确。胸部CT是判断癌症患者新冠肺炎死亡预后的有用工具。确定实验室标志物的预后效用是一个挑战,因为它们的改变值可能起源于肿瘤学或流行病。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
6.30
自引率
0.00%
发文量
134
审稿时长
4-8 weeks
期刊介绍: Pathology & Oncology Research (POR) is an interdisciplinary Journal at the interface of pathology and oncology including the preclinical and translational research, diagnostics and therapy. Furthermore, POR is an international forum for the rapid communication of reviews, original research, critical and topical reports with excellence and novelty. Published quarterly, POR is dedicated to keeping scientists informed of developments on the selected biomedical fields bridging the gap between basic research and clinical medicine. It is a special aim for POR to promote pathological and oncological publishing activity of colleagues in the Central and East European region. The journal will be of interest to pathologists, and a broad range of experimental and clinical oncologists, and related experts. POR is supported by an acknowledged international advisory board and the Arányi Fundation for modern pathology.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信